Clinical Efficacy and Tolerability Evaluation of Pentoxifylline in Rheumatoid Arthritis
| Autor: | P. R. Usha, M. U. R. Naidu, Renuka Datla |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test Visual analogue scale business.industry Arthritis General Medicine medicine.disease Placebo Gastroenterology Pentoxifylline Surgery Tolerability Rheumatoid arthritis Erythrocyte sedimentation rate Internal medicine medicine Pharmacology (medical) business Rheumatism medicine.drug |
| Zdroj: | Clinical Drug Investigation. 22:329-339 |
| ISSN: | 1173-2563 |
| DOI: | 10.2165/00044011-200222050-00007 |
| Popis: | Recent data suggest that cytokines and tumour necrosis factor (TNF) α play a crucial role in the pathophysiology of chronic synovitis in rheumatoid arthritis (RA). Pentoxifylline has been shown to inhibit TNFα and protect against arthritis. The purpose of the present study was to evaluate the clinical efficacy and tolerability of pentoxifylline in patients with RA. Patients of either gender diagnosed as having RA based on American Rheumatism Association criteria who were symptomatic over the last 6 weeks and not receiving any disease-modifying antirheumatic drugs were included. Patients received either pentoxifylline 400mg tablets three times daily or placebo for 24 weeks. They were evaluated by a 28-joint count before treatment and every 2 weeks after treatment for the first month and then at monthly intervals. At every visit, painful and tender joint count and score, pain intensity on a fourpoint scale and on a 100mm visual analogue scale (VAS), swollen joint count and score, and duration of morning stiffness were recorded. A total of 53 patients (28 receiving pentoxifylline and 25 placebo) were enrolled in the study. Significant improvement in clinical and laboratory variables was noted with pentoxifylline compared with placebo. Both tender and swollen joint count reduced significantly from 16.8 ± 2.6 to 12.7 ± 3.4 and 9.5 ± 4.4, and from 6.5 ± 1.1 to 4.3 ± 1.3 and 3.7±1.6 after 12 and 24 weeks, respectively, with pentoxifylline. Placebo did not decrease the above parameters. Pain intensity measured on the VAS reduced from 66.3 ± 5.7 to 51.9 ± 9.8mm with pentoxifylline after 24 weeks; however, there was an apparent increase in pain intensity with placebo. A statistically significant decrease in erythrocyte sedimentation rate, rheumatoid factor immunoglobulin M, C-reactive protein and malondialdehyde was observed with pentoxifylline compared with placebo. The response rate was 57% with pentoxifylline compared with 19% with placebo. Pentoxifylline demonstrated significant antirheumatic activity in patients with RA. It significantly improved signs and symptoms of inflammation and disease activity. Pentoxifylline treatment reduced pain, swelling and joint tenderness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|